申请人:Ding Z. Charles
公开号:US20050209210A1
公开(公告)日:2005-09-22
The present invention relates to rifamycin 3-iminomethylenyl (—CH═N—) derivatives having antimicrobial activities, including activities against drug-resistant microorganisms. The claimed rifamycin derivative has a rifamycin moiety covalently linked to a linker through an iminomethylenyl (—CH═N—) group at the C-3 carbon of the rifamycin moiety and the linker is, in turn, covalently linked to a quinolone structure or its pharmacophore within the DNA gyrase and topoisomerase IV inhibitor family. The inventive rifamycins are novel and exhibit activity against both rifampin and ciprofloxacin-resistant microorganisms.
本发明涉及具有抗微
生物活性的
利福霉素3-
亚甲基亚胺基(—CH═N—)衍
生物,包括对耐药微
生物的活性。所述
利福霉素衍
生物具有
利福霉素基团通过
亚甲基亚胺基(—CH═N—)与连接基团共价连接于
利福霉素基团的C-3碳,并且连接基团与
DNA酶解酶和拓扑异构酶IV
抑制剂家族中的
喹诺酮结构或其药效团共价连接。本发明的
利福霉素是新颖的,并且对
利福平和
环丙沙星耐药微
生物均有活性。